安科生物(300009.SZ):參股公司同種異體CD7-CAR-T細胞藥物“PA3-17注射液”臨牀試驗申請獲受理
格隆匯5月27日丨安科生物(300009.SZ)公佈,今日,公司自國家藥品監督管理局藥品審評中心網站獲知,繼參股公司博生吉醫藥科技(蘇州)有限公司(“博生吉公司”)自體CD7-CAR-T細胞藥物“PA3-17注射液”臨牀試驗申請獲得受理後,博生吉公司申報的同種異體CD7-CAR-T細胞藥物“PA3-17注射液”臨牀試驗申請再次獲得國家藥品監督管理局藥品審評中心受理,受理號為:CXSL21*****國。
此次獲得臨牀試驗受理的是博生吉公司自主研發的另一項針對CD7靶點的同種異體CD7-CAR-T細胞注射液。該注射液是利用患者幹細胞移植供體的T淋巴細胞生產的一種靶向CD7的CAR-T細胞藥物,其適應症為成人異基因移植後復發/難治性CD7陽性血液淋巴系統惡性腫瘤。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.